Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Moderna up 15% on mRNA-2752 data

Published 01/31/2019, 01:06 PM
© Reuters. Moderna up 15% on mRNA-2752 data
AZN
-
MRNA
-
  • Moderna (MRNA +14.6%) is up on average volume, adding to its nascent rally. Shares have risen over 20% since Tuesday.
  • Yesterday, it announced the publication of preclinical data in Science Translational Medicine on pipeline candidate mRNA-2752. Results from a mouse study showed a broad immune response promoting tumor regression in both injected lesions and distant un-uninjected tumors. When combined with checkpoint inhibitors, mRNA-2752 increased complete response rates in immunosuppressive and immunologically barren tumor models that were otherwise unresponsive to checkpoint inhibitor therapy.
  • An open-label Phase 1 study evaluating mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab, in patients with advanced/metastatic solid tumors or lymphoma is in process. The estimated primary completion date is August 2020.
  • Now read: U.S. IPO Weekly Recap: Biggest Biotech Breaks In 3-IPO Week


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.